I graduated from The Queen’s University of Belfast with a BSc (Hons) Biochemistry degree in 1987.
I then joined the Faculty of Medicine at The Queen’s University of Belfast where I spent three years studying for a PhD in Oncology where my research focussed on modulation of growth factor and steroid hormone receptor expression in human breast cancer cells.
Following completion of my PhD, I moved to the University of Liverpool in 1990, where I carried out three years of Post-Doctoral research investigating the role of monocytes and macrophages in tumour cell killing.
I then took up the role of lecturer in Biomedical Science at the University of Wolverhampton in 1993 and Senior lecturer in 1998. I then took on a role as Principal Lecturer and Placement Manager before my current role as Principal Lecturer for Accreditation and Development (PSRB) and Deputising for Head of School.
Continuing Professional Development
Continuing Professional Development – The European Perspective
I am interested in the approaches to Continuing Professional Development (CPD) for Biomedical Scientists in different European Countries. There are different requirements in different European countries for how continued registration/licence is linked to CPD and the requirements for certain amounts and types of CPD and for CPD activities to meet specified accreditation criteria. As there is a spectrum of approaches to CPD within different European countries
I was awarded a grant for 100,000 Euros from the European Commission Leonardo Partnership funding stream for the following project ‘Enhance IT - Enhancing Hospital Laboratory Standards for CPD: A Quality Improvement Toolkit’
Continuing Professional Development – What is the Impact?
I am also interested in the impact of Continuing Professional Development. Although the purposes of CPD are clearly defined by most professional bodies, I am currently ascertaining if CPD activities are actually effective in achieving the overall specified purpose of CPD and how/if this can be effectively measured.
Fellow of the Higher Education Academy
Fellow of the Institute of Biomedical Science
Fellow of the Society of Biology
64. Martin J, Gasljevic V, Šálek T et al (2015) Fifth Transnational Meeting of a European Project to Enhance Hospital Laboratory Standards for Biomedical Scientist's Continuing Professional Development The Biomedical Scientist 59 (6) 330-331
63. Martin J, Buttigieg D Silhavik J et al (2015) Transnational Evaluation of a New Continuing Professional Development Activity for Biomedical Scientists Based on the International Organisation for Standardisation for Medical Laboratories ISO 15189. American Journal of Educational Research in press
62. Martin J Adkins A, Bennett T, Rice K and Taylor Y. (2015) European Project to Enhance Laboratory Standards for Biomedical Scientist CPD: Fourth Transnational Meeting. The Biomedical Scientist 59 (3) 154-156
61. Martin J, Buttigieg D Silhavik J et al (2014k) Enhance It - Enhancing Hospital Laboratory Standards for Continuing Professional Development: Transnational Evaluation of a Novel CPD Activity for Biomedical Scientists. American Journal of Educational Research vol. 2, no. 11, 1110-1114. doi: 10.12691/education-2-11-18.
60. Smith S, Ganesan R and Martin J (2014j) Flipping the postgraduate classroom – is it just another pedagogic fad? Medical Education – submitted
59. Martin J, Gasljevic V, Šálek T, et al (2015a) Comparison of Approaches and Measurement of Continuing Professional Development for Specialists in Laboratory Medicine within Four European Countries. Clinical Chemistry and Laboratory Medicine 53(1): 35–44
58. Smith S and Martin J (2014i) Practitioner Capability: supporting critical reflection during work-based placement – a Pilot study. Higher education, Skills and Work-based learning, Vol. 4 (3) pp. 284 - 300
57. Martin J (2014h) European Project to Enhance Laboratory Standards for Biomedical Scientist CPD: Third Transnational Meeting. The Biomedical Scientist 58 (10) 550-551
56. Martin J (2014g) Service User Involvement in BSc (Hons) Applied Biomedical Science degrees The Biomedical Scientist 58 (12) 668-669
55. Martin J, Adkins A, Bennett T, Rice K and Taylor Y. (2014f) European Project to Enhance Standards for Biomedical Scientist CPD: Developing a Quality Improvement Toolkit. The Biomedical Scientist – (6) 321-323
54. Martin J, Adkins A, Rice K and Taylor, Y (2014e) Undergraduate Biomedical Science Curriculum: Keeping it Relevant to Current Laboratory Practice. The Biomedical Scientist. 58 (5) 266-267
53. Martin J (2014d) Enhancing Laboratory Standards for Continuing Professional Development: a Transnational Project The Biomedical Scientist 58 (5) 262-265
52. Martin J (2014b) European Project to Enhance Continuing Professional Development for Biomedical Scientists. The Biomedical Scientist 58 (3) 155
51. Martin J (2014a) Education, Training and Management at Congress: Developing good practice in pre-registration training. The Biomedical Scientist 58 (2) 76
50. Martin J, Elliott, Y and Johnson E (2014c) Training for New Training Officers: A Combined Aston, Coventry and Wolverhampton Universities Event The Biomedical Scientist 58 (3) 150-153
49. Martin, J (2013f) A European Project to Enhance Hospital Laboratory Standards for Biomedical Scientists Continuing Professional Development by Establishing a Quality Improvement Toolkit and an Online Community of Practice. National Association of Primary Care Review Winter 2013/14, 29-30
48. Martin J, Elliott, Y and Johnson E(2013e) Placement Student Workshops: A Combined Approach by Aston, Coventry and Wolverhampton Universities. The Biomedical Scientist 57 (11) 672-674
47. Smith S and Martin J (2013)Practitioner capability: supporting critical reflection – a pilot study. The Biomedical Scientist 57 (10): 608-609
46. Martin, J (2013d) Combined Aston, Coventry and Wolverhampton Meeting: Training The Trainers Annual Placement Feedback: The Biomedical Scientist 57 (9): 548-551
45. Adkins, A.E., Taylor, Y. and Martin, J.HJ (2013c) Biomedical Science Placement Provision within the West Midlands South Region: Status Quo? The Biomedical Scientist 57 (7) 404-405
44. Martin J, (2013b) Training The Trainers: Combined Aston, Coventry and Wolverhampton Universities Portfolio Peer Review. The Biomedical Scientist 57 (6) 348-349
43. Martin J, (2013a) A Transnational Project to Develop Good Practice in Preregistration Training of Biomedical Scientists: UK and Malta. The Biomedical Scientist57 (1) 42-44
42. Blann A, Dalton J and Martin J (2012d) Putting a Price on Pathology. Health Service Journal. 6th September 2012. Available at <http://www.hsj.co.uk/resource-centre/best-practice/qipp-resources/putting-a- price-on-pathology/5048530.article>
41. Martin, J (2012c) Training The Trainers Annual Placement Feedback: Combined Aston, Coventry and Wolverhampton Meeting. The Biomedical Scientist 56 (9): 563-565
40. Martin J, (2012a) Developing Good Practice in Preregistration Training: a UK/ Malta Transnational project. The Biomedical Scientist 56 (1): 46-47
39. Martin JHJ (2011c) Training The Trainers: A Combined One Day Meeting The Biomedical Scientist 55 (4): 258-261
38. Martin JHJ (2011b) Placement Laboratories: A Combined Approach to Auditing in the West Midlands Region. The Biomedical Scientist 55 (3): 194-195
37. Martin JHJ (2010e) Sharing Good Practice: a one-day meeting for Placement Facilitators. The Biomedical Scientist 54 (12): 874-875
36. Martin JHJ (2010d) Keeping the Undergraduate Biomedical Science Curriculum Relevant to Current Practice: a one day meeting The Biomedical Scientist 54 (9): 656-657
35. Martin JHJ (2010c) Training The Trainers: A Transnational Approach The Biomedical Scientist 54 (8): 572
34. Martin JHJ (2010b) West Midlands Regional Training Event: a one-day meeting The Biomedical Scientist 54 (7): 500-501
33. Martin JHJ (2010a) West Midlands training officers Specialist Portfolio workshops: a one-day meeting The Biomedical Scientist 54 (4): 278-279
32. Martin JHJ (2009) West Midlands training officers workshops: a one-day meeting The Biomedical Scientist 53 (11): 959-960
31.Martin J, (2012b) It doesn’t matter where I sit……… does it? The Effect of Changing Classroom Seating Position on Student Performance and Motivation Factors, Online Educational Research Journal 3:4
30. Lahiri M and Martin JHJ (2009) Nitric oxide decreases motility and increases adhesion in human breast cancer cells. Oncology Reports 21: 275-281
29.Martin JHJ, Crotty S and Nelson PN (2007) Phytoestrogens………Perpetrators or Protectors? Future Oncology 3: 307-318
28 Martin JHJ, Crotty S, Warren P and Nelson PN (2007) Does an apple a day keep the doctor away because a phytoestrogen a day keeps the virus at bay? A review of the anti-viral properties of phytoestrogens. Phytochemistry 68: 266-274
27 Ejthadi HD, Martin JH, Jeung G, Roden DA, Lahiri M, Warren P, Murray PG and Nelson PN (2005) A Novel Multiplex RT-PCR System Detects Human Endogenous Retrovirus-K in Breast Cancer. Arch Virol 150: 177-184
26 Lahiri M and Martin JHJ (2004) Reduced Expression of Endothelial and Inducible Nitric Oxide Synthase in a Multi-drug Resistant Variant of the MCF-7 Human Breast Cancer Cell Line. Oncology Reports 12: 1007-1011
25 P.N. Nelson, P. Hooley, D. Roden, H. Davari Ejtehadi, P. Rylance, P. Warren, J. Martin & P.G. Murray (2004) Human Endogenous Retroviruses: Transposable Elements with Potential? Clin Exp Immunol 138: 1-9
24.Martin JHJ, Symonds A and Chohan S (2003) Down-Regulation of Nitric Oxide Production by Droloxifene and Toremifene in Human Breast Cancer Cells. Oncology Reports 10: 979-84
23.Nelson PN, Davari Ejtehadi H, Carnegie P, Roden D, Martin J, Rowland-Jones S, Hooley P, Astley J and Murray PG (2003) Demystified….Human Endogenous Retroviruses. J Clin Path; Mol Path 56, 11-18.
22.Smyth M, Pettitt T, Symonds A and Martin J (2003) Identification of the Pocket Factors in a Picornavirus. ArchivesVirol 148: 1225-33.
21.Smyth MS, Symonds A, Brazinova S and Martin JHJ (2002) Bovine Enterovirus as an Oncolytic Virus: Foetal Calf Serum Facilitates its infection of Human Cells. Int. J. Mol. Med. 10, 49-53
20.Martin, J.H.J. Symonds A, and Chohan S. (2002) Down-Regulation of Nitric Oxide Production by Droloxifene and Toremifene in Human Breast CancerCells: Interferon Alpha has No Further Effect. The Internet Journal of Oncology. 1, (2).
19.Smyth, M.S.and Martin, JHJ (2002) Picornavirus Uncoating. J Clin Path; Mol Path 55: 214-219
18.Martin JHJ and Symonds A (2002) Synergistic Antitumour Effect of a Combination of Toremifene and Interferon Alpha on ZR-75-1 Human Breast Cancer Cells: Dependence on Interferon Alpha Subtype. Oncology Reports 9, 379-382
17.Smyth, M.S. & Martin, J.H.J. (2001)Structural, biochemical and electrostatic basis of serotype specificity in bovine enteroviruses.Archives Virol. 146, 347-355
16.Martin, J.H.J. Alalami, O. and Yaqoob, F (2000) Differential effects of retinoids on nitric oxide production by promonocytic U937 cells and ZR-75-1 human breast cancer cells. Oncology Rep. 7, 219-223
15.Smyth, M.S.and Martin, J.H.J. (2000) X-ray crystallography. J Clin Path; Mol Path 53, 8-14
14.Smyth, M., Trudgett, A., Martin, J., Hoey, E. and Martin S. (2000) Conformational changes during proteolytic processing of picornavirus capsid proteins. Archives Virol. 145, 1473-1479
13 Martin, J.H.J., Begum, S., Alalami, O., Harrison, A. and Scott, K. (2000) Endothelial Nitric Oxide Synthase: Correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumor Biol. 21, 90-97
12.Jamil, I., Symonds, A., Lynch, S., Alalami, O., Smyth, M. and Martin J. (1999) Divergenteffects of paracetamol on reactive oxygen intermediate and reactive nitrogen intermediate production by U937 cells Int. J. Mol. Med. 4, 309-312
11. Martin, J.H.J. Alalami,O. & van den Berg, H.W.(1999) Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence.Cancer Letts 144, 65-74
10.Alalami, O., Sammons, J., Martin, J.H.J. and Hassan, H.T.(1998)Divergent Effect of Taxol on Proliferation, Apoptosis and Nitric Oxide Production in MHH225 CD34 Positive and U937 CD34 Negative Human Leukaemia Cells.Leukemia Res., 22, 939-945
9. Alalami, O. and Martin, J.H.J. (1998) ZR-75-1 Human Breast Cancer Cells Expression of Inducible Nitric Oxide Synthase and Effect of Tamoxifen and Phorbol Ester on Nitric Oxide Production Cancer Letts., 123, 99-105
8. Davies, J.I., Smyth, M.S. and Martin, J.H.J. (1997) Automated Reticulocyte Counting. Evaluation of the Coulter STKS Haematology Analyser Reticulocyte Counting Function Clin and Lab Haematol. 19, 89 -92
7. Martin, J.H.J. and Alalami, O. (1996) Tamoxifen inhibits phorbol ester-induced reactive nitrogen intermediate production by U937 cells. Oncology Rep. 3, 935- 937
6. Martin, J.H.J. and Edwards, S.W. (1994) Interferon-gamma enhances monocyte cytotoxicity via enhanced reactive oxygen intermediate production. Absence of an effect on macrophage cytotoxicity is due to failure to enhance reactive nitrogen intermediate production. Immunology, 81, 592-597
5. van den berg, H.W., Lynch, M and Martin, J.H.J. (1993) The relationship between affinity of progestins and anti-progestins for the progesterone receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: evidence for heterospecific receptor modulation via the glucocorticoid receptor. Eur. J. Cancer, 29, 1771-1775
4. Martin, J.H.J. and Edwards, S.W. (1993) Changes in mechanisms of monocyte/macrophage mediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity whereas reactive nitrogen intermediates are employed by macrophages in tumour cell killing. J. Immunol., 150, 3478-3486
3. Martin, J.H.J., McKibben, B., Lynch, M and van den Berg, H.W. (1991) Modulation by oestrogen and progestins/antiprogestins of alpha interferon receptor expression in human breast cancer cells. Eur. J. Cancer, 27, 143-146
2. van den Berg, H.W., Martin, J. and Lynch, M. (1990) High progesterone receptorconcentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen-free conditions. Br. J. Cancer, 61, 504-507
1. van den Berg, H.W., Lynch, M., Martin, J., Nelson, J., Dickson, G.R. and Crockard, A.D. (1989) Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and stability of the resistant phenotype. Br. J. Cancer, 59, 522-526